Shire has acquired Switzerland-based source plasma collection firm Sanaplasma to support the growth of its immunology business by extending long-term access to plasma.

Financial details of the deal have not been disclosed.

Sanaplasma primarily works on collection of source plasma. It operates through 14 plasmapheresis centres in Europe; 11 in the Czech Republic and the remaining three in Hungary.

The firm will be added to Shire’s plasma collection network in Europe. Shire expects the acquired firm to complement its established plasma supply and manufacturing capabilities.

Plasma is required to manufacture immunoglobulin therapies that are intended to treat patients suffering from some types of rare immunological diseases.

Shire BioLife Plasma Services Global Operations vice-president Sue Brown said: “The acquisition of Sanaplasma demonstrates Shire’s commitment to its rapidly growing and leading immunology business.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The combination of Sanaplasma’s 14 plasma centres in the Czech Republic and Hungary with our more than 100 BioLife centres in the US and Austria will help us to meet the continuously growing demand for plasma-derived medicines.”

“The acquisition of Sanaplasma demonstrates Shire’s commitment to its rapidly growing and leading immunology business.”

Sanaplasma co-owner Dr Martin Lukas said: “I look forward to working with the team at Shire during the transition to help ensure continuity of supply, know-how transfer, and a smooth handover to position the business for future success as it continues to meet patient needs.”

Shire’s largest franchise, Immunology, recorded 18% growth to reach $4.4bn in product sales on a pro-forma basis last year.

The portfolio of the immunology franchise includes treatments for hereditary angioedema, primary and secondary immunodeficiency, and rare autoimmune and neurological disorders. These therapies can be tailored based on needs of individual patients.

Apart from treatments, the franchise also offers specialised services and other offerings to help patients.

The sanaplasma acquisition follows Shire’s sale of its Oncology unit earlier this month to French company Servier for $2.4bn.